CureVac Statistics
Total Valuation
CureVac has a market cap or net worth of $815.06 million. The enterprise value is $356.65 million.
| Market Cap | 815.06M |
| Enterprise Value | 356.65M |
Important Dates
The next estimated earnings date is Thursday, May 22, 2025, before market open.
| Earnings Date | May 22, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CureVac has 225.16 million shares outstanding. The number of shares has increased by 1.57% in one year.
| Current Share Class | 225.16M |
| Shares Outstanding | 225.16M |
| Shares Change (YoY) | +1.57% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 5.64% |
| Owned by Institutions (%) | 17.04% |
| Float | 125.69M |
Valuation Ratios
The trailing PE ratio is 4.86.
| PE Ratio | 4.86 |
| Forward PE | n/a |
| PS Ratio | 1.47 |
| Forward PS | n/a |
| PB Ratio | 1.13 |
| P/TBV Ratio | 1.17 |
| P/FCF Ratio | 8.39 |
| P/OCF Ratio | 7.73 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 1.55, with an EV/FCF ratio of 3.67.
| EV / Earnings | 2.12 |
| EV / Sales | 0.64 |
| EV / EBITDA | 1.55 |
| EV / EBIT | 1.64 |
| EV / FCF | 3.67 |
Financial Position
The company has a current ratio of 7.28, with a Debt / Equity ratio of 0.06.
| Current Ratio | 7.28 |
| Quick Ratio | 7.11 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.17 |
| Debt / FCF | 0.42 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 26.73% and return on invested capital (ROIC) is 20.26%.
| Return on Equity (ROE) | 26.73% |
| Return on Assets (ROA) | 16.48% |
| Return on Invested Capital (ROIC) | 20.26% |
| Return on Capital Employed (ROCE) | 28.72% |
| Revenue Per Employee | $563,656 |
| Profits Per Employee | $170,816 |
| Employee Count | 983 |
| Asset Turnover | 0.67 |
| Inventory Turnover | 8.34 |
Taxes
In the past 12 months, CureVac has paid $29.71 million in taxes.
| Income Tax | 29.71M |
| Effective Tax Rate | 15.03% |
Stock Price Statistics
The stock price has increased by +24.40% in the last 52 weeks. The beta is 2.43, so CureVac's price volatility has been higher than the market average.
| Beta (5Y) | 2.43 |
| 52-Week Price Change | +24.40% |
| 50-Day Moving Average | 3.12 |
| 200-Day Moving Average | 3.19 |
| Relative Strength Index (RSI) | 60.86 |
| Average Volume (20 Days) | 545,463 |
Short Selling Information
The latest short interest is 4.99 million, so 2.21% of the outstanding shares have been sold short.
| Short Interest | 4.99M |
| Short Previous Month | 4.80M |
| Short % of Shares Out | 2.21% |
| Short % of Float | 3.97% |
| Short Ratio (days to cover) | 7.87 |
Income Statement
In the last 12 months, CureVac had revenue of $554.07 million and earned $167.91 million in profits. Earnings per share was $0.75.
| Revenue | 554.07M |
| Gross Profit | 444.71M |
| Operating Income | 217.19M |
| Pretax Income | -297.84M |
| Net Income | 167.91M |
| EBITDA | 230.42M |
| EBIT | 217.19M |
| Earnings Per Share (EPS) | $0.75 |
Balance Sheet
The company has $498.76 million in cash and $40.34 million in debt, giving a net cash position of $458.41 million or $2.04 per share.
| Cash & Cash Equivalents | 498.76M |
| Total Debt | 40.34M |
| Net Cash | 458.41M |
| Net Cash Per Share | $2.04 |
| Equity (Book Value) | 721.20M |
| Book Value Per Share | 3.21 |
| Working Capital | 470.10M |
Cash Flow
In the last 12 months, operating cash flow was $105.45 million and capital expenditures -$14.82 million, giving a free cash flow of $97.11 million.
| Operating Cash Flow | 105.45M |
| Capital Expenditures | -14.82M |
| Free Cash Flow | 97.11M |
| FCF Per Share | $0.43 |
Margins
Gross margin is 80.26%, with operating and profit margins of 39.20% and 30.30%.
| Gross Margin | 80.26% |
| Operating Margin | 39.20% |
| Pretax Margin | 35.67% |
| Profit Margin | 30.30% |
| EBITDA Margin | 41.59% |
| EBIT Margin | 39.20% |
| FCF Margin | 17.53% |
Dividends & Yields
CureVac does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.57% |
| Shareholder Yield | -1.57% |
| Earnings Yield | 20.60% |
| FCF Yield | 11.91% |
Analyst Forecast
The average price target for CureVac is $14.00, which is 286.74% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $14.00 |
| Price Target Difference | 286.74% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | -13.85% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CureVac has an Altman Z-Score of 3.55 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.55 |
| Piotroski F-Score | 6 |